Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
HIES
MCID: HYP458
MIFTS: 54

Hyper Ige Syndrome (HIES)

Categories: Blood diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hyper Ige Syndrome

About this section

MalaCards integrated aliases for Hyper Ige Syndrome:

Name: Hyper Ige Syndrome 12 52
Hyper-Ige Syndrome 58 36 29 54 6
Hyperimmunoglobulin E Syndrome 52 39
Hyper-Ige Recurrent Infection Syndrome 52
Hyper Immunoglobulin E Syndrome 12
Hartnup Disease 71
Job Syndrome 71
Hyper Ige 74
Hies 52

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare immunological diseases


External Ids:

Disease Ontology 12 DOID:0080545
KEGG 36 H01968
ICD10 32 D82.4
ICD10 via Orphanet 33 D82.4
UMLS via Orphanet 72 C3887645
Orphanet 58 ORPHA331223
UMLS 71 C0018609 C3887645
Sources

Summaries for Hyper Ige Syndrome

About this section
KEGG : 36 Hyper-IgE syndrome (HIES) is a complex primary immunodeficiency characterized by atopic dermatitis associated with extremely high serum IgE levels and susceptibility to infections with extracellular bacteria. Most cases of HIES are sporadic although can be inherited as autosomal dominant and autosomal recessive traits. One of the involved genes in pathogenesis of HIES is STAT3 that causes autosomal dominant type. In most sporadic and autosomal dominant cases, the HIES is part of a multisystem disorder including abnormalities of the soft tissue, skeletal, and dental systems. In contrast, those with autosomal recessive-HIES have severe molluscum contagiosum and viral infections and may develop severe neurological complications. Recently, It has been reported that mutations in DOCK8, TYK2, and PGM3 cause autosomal recessive HIES.

MalaCards based summary : Hyper Ige Syndrome, also known as hyper-ige syndrome, is related to hyper ige recurrent infection syndrome 1 and chronic mucocutaneous candidiasis, and has symptoms including seizures An important gene associated with Hyper Ige Syndrome is STAT3 (Signal Transducer And Activator Of Transcription 3), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Pathways in cancer. The drugs Miconazole and Posaconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and heart, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Disease Ontology : 12 A hyperimmunoglobulin syndrome that is characterized by eczema, distinct facial features, a tendency to experience bone fractures and recurrent bacterial infections of the skin and lungs.

NIH Rare Diseases : 52 Hyper IgE syndromes (HIES) are rare primary immune deficiencies characterized by elevated serum IgE , skin inflammation (dermatitis) and recurrent skin and lung infections. There are two forms of HIES, which have the above characteristics in common but otherwise have distinct presentations, courses and outcomes: autosomal dominant HIES (AD-HIES) and autosomal recessive HIES (AR-HIES). Click on the embedded links to learn more about autosomal dominant HIES (or Job syndrome) and autosomal recessive HIES.

Wikipedia : 74 Hyperimmunoglobulinemia E syndrome (HIES), of which the autosomal dominant form is called Job's syndrome... more...

Sources

Related Diseases for Hyper Ige Syndrome

About this section

Diseases related to Hyper Ige Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1539)
# Related Disease Score Top Affiliating Genes
1 hyper ige recurrent infection syndrome 1 32.7 STAT3 PGM3 DOCK8
2 chronic mucocutaneous candidiasis 31.5 STAT3 IL4 IFNG DOCK8
3 nail disease 30.1 STAT3 DOCK8
4 candidiasis 30.1 STAT3 IL4 IFNG
5 dermatitis 30.1 STAT3 IL4 IGHE IFNG
6 eczema herpeticum 30.0 IFNG DOCK8
7 combined t cell and b cell immunodeficiency 29.8 STAT3 IL4 DOCK8
8 folliculitis 29.8 IL4 IFNG
9 aspergillosis 29.8 STAT3 IL4 IFNG
10 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 29.7 IL4 DOCK8
11 strongyloidiasis 29.7 IGHE IFNG
12 orofacial granulomatosis 29.5 IL4 IFNG
13 otitis media 29.4 IL4 IGHE IFNG
14 lung abscess 29.4 STAT3 IGES IFNG DOCK8
15 echinococcosis 29.3 IGHE IFNG
16 clonorchiasis 29.2 IGHE IFNG
17 hypereosinophilic syndrome 29.1 STAT3 IL4 IGHE IGES IFNG
18 cystic echinococcosis 29.1 IGHE IFNG
19 crohn's disease 29.1 STAT3 IL4 IFNG
20 poliomyelitis 29.1 IL4 IFNG
21 milk allergy 29.1 IL4 IGHE IGES
22 conjunctivitis 29.0 IL4 IGHE IFNG
23 schistosomiasis 29.0 IL4 IGHE IFNG
24 colitis 28.9 STAT3 IL4 IFNG
25 chickenpox 28.9 IL4 IFNG DOCK8
26 common variable immunodeficiency 28.9 STAT3 IL4 IFNG
27 bronchiolitis 28.9 IL4R IL4 IFNG
28 opisthorchiasis 28.9 IL4 IGES
29 allergic bronchopulmonary aspergillosis 28.8 IL4 IGHE IGES IFNG
30 parasitic helminthiasis infectious disease 28.8 IL4R IL4 IFNG
31 acute graft versus host disease 28.8 IL4 IFNG
32 scleritis 28.8 IL4 IFNG
33 dermatitis, atopic 28.7 STAT3 IL4R IL4 IGHE IGES IFNG
34 arthritis 28.6 STAT3 IL6ST IL4 IFNG
35 ige responsiveness, atopic 28.6 IL4R IL4 IGHE IGES IFNG
36 toxoplasmosis 28.5 STAT3 IL4 IFNG
37 idiopathic interstitial pneumonia 28.5 IL4R IL4 IFNG
38 bone inflammation disease 28.5 STAT3 IL4 IFNG
39 respiratory allergy 28.4 IL4R IL4 IGHE
40 severe combined immunodeficiency 28.4 PGM3 IL4R IL4 IFNG
41 rhinitis 28.4 IL4R IL4 IGHE IFNG
42 multiple sclerosis 28.3 STAT3 IL4R IL4 IFNG
43 food allergy 28.3 IL4R IL4 IGHE IGES IFNG
44 allergic asthma 28.1 IL4R IL4 IGHE IFNG
45 renal cell carcinoma, nonpapillary 28.0 STAT3 IL4R IL4 IFNG
46 inflammatory bowel disease 27.9 STAT3 IL6ST IL4R IL4 IFNG
47 allergic rhinitis 27.8 IL4R IL4 IGHE IGES IFNG
48 allergic hypersensitivity disease 27.8 IL4R IL4 IGHE IGES IFNG
49 asthma 27.4 IL4R IL4 IGHE IGES IFNG
50 erythroderma, congenital, with palmoplantar keratoderma, hypotrichosis, and hyper-ige 12.8

Graphical network of the top 20 diseases related to Hyper Ige Syndrome:



Diseases related to Hyper Ige Syndrome
Sources

Symptoms & Phenotypes for Hyper Ige Syndrome

About this section

UMLS symptoms related to Hyper Ige Syndrome:


seizures

MGI Mouse Phenotypes related to Hyper Ige Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.8 IFNG IL4 IL4R IL6ST PGM3 STAT3
2 endocrine/exocrine gland MP:0005379 9.73 IFNG IL4 IL4R IL6ST PGM3 STAT3
3 hematopoietic system MP:0005397 9.7 DOCK8 IFNG IL4 IL4R IL6ST PGM3
4 immune system MP:0005387 9.5 DOCK8 IFNG IL4 IL4R IL6ST PGM3
5 liver/biliary system MP:0005370 9.02 IFNG IL4 IL4R IL6ST STAT3
Sources

Drugs & Therapeutics for Hyper Ige Syndrome

About this section

Drugs for Hyper Ige Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
2
Posaconazole Approved, Investigational, Vet_approved Phase 3 171228-49-2 147912
3 Anti-Infective Agents Phase 3
4 Antiparasitic Agents Phase 3
5 Antiprotozoal Agents Phase 3
6 Antifungal Agents Phase 3
7 Cytochrome P-450 Enzyme Inhibitors Phase 3
8 Hormone Antagonists Phase 3
9 Steroid Synthesis Inhibitors Phase 3
10 Hormones Phase 3
11
Amphotericin B Approved, Investigational Phase 2 1397-89-3 14956 5280965
12
Histamine Approved, Investigational Phase 2 51-45-6 774
13
Sodium citrate Approved, Investigational Phase 2 68-04-2
14
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
15 Immunoglobulins Phase 2
16 Antibodies Phase 2
17 Vaccines Phase 2
18 Immunologic Factors Phase 2
19 Agglutinins Phase 2
20 Anti-Bacterial Agents Phase 2
21 Liposomal amphotericin B Phase 2
22 Autoantibodies Phase 2
23 Gastrointestinal Agents Phase 2
24 Neurotransmitter Agents Phase 2
25 Anti-Ulcer Agents Phase 2
26
Histamine Phosphate Phase 2 51-74-1 65513
27 Bismuth tripotassium dicitrate Phase 2
28 Histamine H2 Antagonists Phase 2
29 Citrate Phase 2
30 Histamine Antagonists Phase 2
31 Ranitidine bismuth citrate Phase 2
32
Bismuth Phase 2 7440-69-9 16682734 105143
33 Antacids Phase 2
34
Omalizumab Approved, Investigational Phase 1 242138-07-4
35
Warfarin Approved Phase 1 81-81-2 6691 54678486
36 Respiratory System Agents Phase 1
37 Anti-Asthmatic Agents Phase 1
38 Anti-Allergic Agents Phase 1
39 Pharmaceutical Solutions Phase 1
40 Coagulase
41 Yellow Dock

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections Completed NCT00033982 Phase 3 Posaconazole
2 A Phase 2a Study to Evaluate the Safety, Tolerability, and Immunogenicity of One Dose of NDV-3A Vaccine in Patients With STAT3-Mutated Hyper-IgE Syndrome Completed NCT02996448 Phase 2 NDV-3A
3 A Phase 2a Efficacy, Safety, Tolerability, and PK Study of Encochleated Amphotericin B (CAMB/MAT2203) in Patients With Mucocutaneous Candidiasis Who Are Refractory or Intolerant to Standard Non-Intravenous Therapies Active, not recruiting NCT02629419 Phase 2 Amphotericin B
4 Bilateral Orthotopic Lung Transplant in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant From Partially HLA-Matched Cadaveric Donors Enrolling by invitation NCT01852370 Phase 1, Phase 2
5 A Double-Blind, Randomized, Placebo-Controlled Cross-Over Study Assessing the Role of Pathogen-Specific IgE and Histamine Release in the Hyper-IgE Syndrome and the Effect of Ranitidine on Laboratory and Clinical Manifestations Terminated NCT00527878 Phase 2 Ranitidine;Placebo
6 Pilot Study of Omalizumab (Xolair) in Hyper IgE (Job's) Syndrome Completed NCT00260702 Phase 1 Omalizumab (Xolair)
7 Diagnostic Efficacy of Virtual Bronchoscopy Completed NCT00001515 Phase 1
8 Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of Glycosylation Terminated NCT02511041 Phase 1 N-Acetylglucosamine (GlcNAc);Uridine
9 NFIL3-induced Pathological Enhancement of IgE Class Switch Recombination in Hyper-IgE Syndrome Unknown status NCT02228941
10 Validation Study of mHealth Technology in HIV to Improve Empowerment and Healthcare Utilisation: Research and Innovation to Generate Evidence for Personalised Care (EmERGE) Unknown status NCT02904733
11 Human Immunity Against Staphylococcus Aureus Skin Infection Completed NCT02262819 S. aureus
12 Genetic Disorders of Mucociliary Clearance Completed NCT00368446
13 Cognitive Function in Leukocyte Disorders Completed NCT00005933
14 Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES) Recruiting NCT00006150
15 Studies of Skin Microflora in Healthy Individuals and Atopic Dermatitis Patients Recruiting NCT00605878
16 Oral Microbial and Immunological Characterization of Patients With Immune Dysfunction Recruiting NCT01568697
17 NIH Participation to USIDNET Registry Recruiting NCT01953016
18 Natural History, Genetics, Phenotype and Treatment of Mycobacterial Infections Recruiting NCT00018044
19 Skin Immunity Sample Collection Involving Blisters and Biopsies Not yet recruiting NCT03921515 Early Phase 1

Search NIH Clinical Center for Hyper Ige Syndrome

Sources

Genetic Tests for Hyper Ige Syndrome

About this section

Genetic tests related to Hyper Ige Syndrome:

# Genetic test Affiliating Genes
1 Hyper-Ige Syndrome 29
Sources

Anatomical Context for Hyper Ige Syndrome

About this section

MalaCards organs/tissues related to Hyper Ige Syndrome:

40
Skin, Lung, Heart, T Cells, Bone, B Cells, Liver
Sources

Publications for Hyper Ige Syndrome

About this section

Articles related to Hyper Ige Syndrome:

(show top 50) (show all 576)
# Title Authors PMID Year
1
Reduced expression of chemoattractant receptors by polymorphonuclear leukocytes in Hyper IgE Syndrome patients. 54 61
20005258 2010
2
Uncovering an IL-10-dependent NF-kappaB recruitment to the IL-1ra promoter that is impaired in STAT3 functionally defective patients. 54 61
20032313 2010
3
A novel mutation in the signal transducer and activator of transcription 3 (STAT3) gene, in hyper-IgE syndrome. 54 61
20149460 2010
4
Rapid molecular analysis of the STAT3 gene in Job syndrome of hyper-IgE and recurrent infectious diseases. 54 61
20093388 2010
5
Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. 54 61
20159255 2010
6
Hyper-IgE syndrome with STAT3 mutation: a case report in Mainland China. 54 61
20490271 2010
7
Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. 54 61
20004785 2009
8
Hyper-IgE syndrome. 54 61
19717292 2009
9
TH17 cells and regulatory T cells in primary immunodeficiency diseases. 54 61
19410687 2009
10
STAT3 single-nucleotide polymorphisms and STAT3 mutations associated with hyper-IgE syndrome are not responsible for increased serum IgE serum levels in asthma families. 54 61
18841165 2009
11
Hyper IgE syndrome with umbilical hernia. 54 61
20101344 2009
12
[Hyper-IgE syndrome with mutation in STAT3 gene - case report and literature review]. 54 61
19648655 2009
13
Rare association of hyper IgE syndrome with cervical rib and natal teeth. 54 61
20101342 2009
14
Elevated serum immunoglobulin E (IgE): when to suspect hyper-IgE syndrome-A 10-year pediatric tertiary care center experience. 54 61
19331717 2009
15
Insights into the role of STAT3 in human lymphocyte differentiation as revealed by the hyper-IgE syndrome. 54 61
19109129 2009
16
Primary immune deficiencies with aberrant IgE production. 54 61
19084106 2008
17
Reduced memory B cells in patients with hyper IgE syndrome. 54 61
18835223 2008
18
Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3. 54 61
18978467 2008
19
Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups. 54 61
18706697 2008
20
Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. 54 61
18602572 2008
21
Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. 54 61
18591410 2008
22
Histopathologic Findings of Pneumatocele in a Patient with Hyper-IgE syndrome, compatible with cystic adenomatoid malformation. 54 61
18552413 2008
23
Fournier gangrene associated with hyper IgE syndrome (Job syndrome). 54 61
18380833 2008
24
[STAT3 mutation identified in patients with Hyper-IgE syndrome]. 54 61
18334168 2008
25
Hyperimmunoglobulin E syndrome (Job's syndrome). 54 61
19284090 2008
26
STAT3 mutations in the hyper-IgE syndrome. 54 61
17881745 2007
27
Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. 54 61
17676033 2007
28
[Allergic disease with IgE hypersynthesis. Proposal of a new denomination for an allergic disease confused with immunodeficiency]. 54 61
18297852 2007
29
Causes of death in hyper-IgE syndrome. 54 61
17335882 2007
30
The hyper IgE syndrome and mutations in TYK2. 54 61
17521577 2007
31
[Pneumocystis carinii pneumonia in a patient with hyper-IgE syndrome]. 54 61
17554982 2007
32
Hyper IgE syndrome: review and future directions. 54 61
20477605 2005
33
No indication for a defect in toll-like receptor signaling in patients with hyper-IgE syndrome. 54 61
16133988 2005
34
Production of biologically active recombinant human soluble CD23 and its effect on PBMCs isolated from hyper-IgE blood. 54 61
16083870 2005
35
Non-Hodgkin's lymphoma in Job's syndrome: a case report and literature review. 54 61
15621772 2004
36
Cow's milk allergy in a patient with hyper-IgE syndrome. 54 61
15104201 2004
37
[28-Year-Old Patient with Elevated Serum IgE Levels and Multiple Refractory Epidural and Paravertebral Abscesses. Clinical manifestation of a Job's Syndrome?]. 54 61
14551710 2003
38
Selective insufficiency of IFN-gamma secretion in patients with hyper-IgE syndrome. 54 61
12708982 2003
39
Hyper immunoglobulin-E syndrome: a case with chronic ear draining mimicking polypoid otitis media. 54 61
12663115 2003
40
[Anesthetic management for a patient with hyper-IgE syndrome]. 54 61
12649874 2003
41
Detection and characterization of plasma cells in peripheral blood: correlation of IgE+ plasma cell frequency with IgE serum titre. 54 61
12452825 2002
42
[Manifestation of hyper-IgE syndrome in advanced HIV-1 infection]. 54 61
11831060 2002
43
Cytokine and chemokine dysregulation in hyper-IgE syndrome. 54 61
11414745 2001
44
[Loss of an eye due to hyper-IgE syndrome after corneal transplantation]. 54 61
11198964 2001
45
[Hyper-IgE syndrome treated with interferon alpha 2 beta. Report of a case]. 54 61
11558395 2000
46
The relationship between serum IgE and surface levels of FcepsilonR on human leukocytes in various diseases: correlation of expression with FcepsilonRI on basophils but not on monocytes or eosinophils. 54 61
10984372 2000
47
Bone marrow transplantation does not correct the hyper IgE syndrome. 54 61
10871737 2000
48
Defective interleukin-12/interferon-gamma pathway in patients with hyperimmunoglobulinemia E syndrome. 54 61
10657822 2000
49
Increase in granulocyte-macrophage-colony-stimulating factor secretion and the respiratory burst with decreased L-selectin expression in hyper-IgE syndrome patients. 54 61
10507271 1999
50
Pentasomy X and hyper IgE syndrome: co-existence of two distinct genetic disorders. 54 61
10485303 1999
Sources

Variations for Hyper Ige Syndrome

About this section

ClinVar genetic disease variations for Hyper Ige Syndrome:

6 (show top 50) (show all 171) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PGM3 NM_015599.3(PGM3):c.1016_1018AAG[1] (p.Glu340del)short repeat Pathogenic 156471 rs267608259 6:83888400-83888402 6:83178681-83178683
2 STAT3 NM_139276.2(STAT3):c.1909G>A (p.Val637Met)SNV Pathogenic 18308 rs113994139 17:40474492-40474492 17:42322474-42322474
3 PGM3 NM_015599.3(PGM3):c.248T>C (p.Leu83Ser)SNV Pathogenic 133320 rs267608260 6:83898474-83898474 6:83188755-83188755
4 PGM3 NM_015599.3(PGM3):c.1504G>T (p.Asp502Tyr)SNV Pathogenic 133321 rs267608261 6:83880059-83880059 6:83170340-83170340
5 STAT3 NM_139276.2(STAT3):c.1234A>T (p.Thr412Ser)SNV Pathogenic 633433 rs1567713850 17:40481475-40481475 17:42329457-42329457
6 STAT3 NM_139276.2(STAT3):c.1979T>C (p.Met660Thr)SNV Pathogenic/Likely pathogenic 265261 rs886039434 17:40474422-40474422 17:42322404-42322404
7 DOCK8 NM_203447.3(DOCK8):c.380G>A (p.Arg127His)SNV Conflicting interpretations of pathogenicity 366538 rs150742426 9:289557-289557 9:289557-289557
8 DOCK8 NM_203447.3(DOCK8):c.2862A>T (p.Pro954=)SNV Conflicting interpretations of pathogenicity 366955 rs117610764 9:386414-386414 9:386414-386414
9 DOCK8 NM_203447.3(DOCK8):c.663C>A (p.Asp221Glu)SNV Conflicting interpretations of pathogenicity 366546 rs139391329 9:312088-312088 9:312088-312088
10 DOCK8 NM_203447.3(DOCK8):c.3519C>T (p.Ala1173=)SNV Conflicting interpretations of pathogenicity 366976 rs144299704 9:407058-407058 9:407058-407058
11 DOCK8 NM_203447.3(DOCK8):c.3606T>C (p.Cys1202=)SNV Conflicting interpretations of pathogenicity 366993 rs143919622 9:414857-414857 9:414857-414857
12 DOCK8 NM_203447.3(DOCK8):c.3813A>G (p.Lys1271=)SNV Conflicting interpretations of pathogenicity 366995 rs75411647 9:418180-418180 9:418180-418180
13 DOCK8 NM_203447.3(DOCK8):c.3058A>G (p.Ile1020Val)SNV Conflicting interpretations of pathogenicity 218873 rs151094543 9:396872-396872 9:396872-396872
14 DOCK8 NM_203447.3(DOCK8):c.3543A>G (p.Val1181=)SNV Conflicting interpretations of pathogenicity 227329 rs753242273 9:414794-414794 9:414794-414794
15 DOCK8 NM_203447.3(DOCK8):c.3022C>T (p.Arg1008Trp)SNV Conflicting interpretations of pathogenicity 178767 rs16937932 9:396836-396836 9:396836-396836
16 DOCK8 NM_203447.3(DOCK8):c.5211G>A (p.Glu1737=)SNV Conflicting interpretations of pathogenicity 137150 rs34098809 9:439376-439376 9:439376-439376
17 DOCK8 NM_203447.3(DOCK8):c.5491-7T>ASNV Conflicting interpretations of pathogenicity 137151 rs184867151 9:443420-443420 9:443420-443420
18 DOCK8 NM_203447.3(DOCK8):c.452G>A (p.Arg151Gln)SNV Conflicting interpretations of pathogenicity 366540 rs149918318 9:304628-304628 9:304628-304628
19 DOCK8 NM_203447.3(DOCK8):c.550G>A (p.Val184Met)SNV Conflicting interpretations of pathogenicity 366544 rs143461644 9:311975-311975 9:311975-311975
20 DOCK8 NM_203447.3(DOCK8):c.828-7A>GSNV Conflicting interpretations of pathogenicity 366578 rs200243583 9:325664-325664 9:325664-325664
21 DOCK8 NM_203447.3(DOCK8):c.6201A>G (p.Glu2067=)SNV Conflicting interpretations of pathogenicity 367094 rs145573166 9:463649-463649 9:463649-463649
22 DOCK8 NM_203447.3(DOCK8):c.3220C>A (p.His1074Asn)SNV Conflicting interpretations of pathogenicity 366969 rs150298985 9:399245-399245 9:399245-399245
23 DOCK8 NM_203447.3(DOCK8):c.4024-4C>TSNV Conflicting interpretations of pathogenicity 366996 rs111306749 9:420945-420945 9:420945-420945
24 DOCK8 NM_203447.3(DOCK8):c.5223+4A>GSNV Conflicting interpretations of pathogenicity 367023 rs117109271 9:439392-439392 9:439392-439392
25 DOCK8 NM_203447.3(DOCK8):c.3270T>C (p.Ile1090=)SNV Uncertain significance 366973 rs377297446 9:404953-404953 9:404953-404953
26 DOCK8 NM_203447.3(DOCK8):c.3312G>C (p.Glu1104Asp)SNV Uncertain significance 366974 rs138810908 9:404995-404995 9:404995-404995
27 DOCK8 NM_203447.3(DOCK8):c.3790G>T (p.Ala1264Ser)SNV Uncertain significance 366994 rs886063955 9:418157-418157 9:418157-418157
28 DOCK8 NM_203447.3(DOCK8):c.*847A>GSNV Uncertain significance 367105 rs924532099 9:465066-465066 9:465066-465066
29 STAT3 NM_139276.2(STAT3):c.*2343_*2344deldeletion Uncertain significance 323205 rs886052928 17:40465419-40465420 17:42313401-42313402
30 STAT3 NM_139276.2(STAT3):c.*1850C>TSNV Uncertain significance 323214 rs886052933 17:40465913-40465913 17:42313895-42313895
31 STAT3 NM_139276.2(STAT3):c.*1850C>GSNV Uncertain significance 323215 rs886052933 17:40465913-40465913 17:42313895-42313895
32 STAT3 NM_139276.2(STAT3):c.*1675T>CSNV Uncertain significance 323216 rs886052934 17:40466088-40466088 17:42314070-42314070
33 STAT3 NM_139276.2(STAT3):c.*1266G>ASNV Uncertain significance 323226 rs886052938 17:40466497-40466497 17:42314479-42314479
34 STAT3 NM_139276.2(STAT3):c.*646T>CSNV Uncertain significance 323234 rs886052939 17:40467117-40467117 17:42315099-42315099
35 STAT3 NM_139276.2(STAT3):c.2216A>G (p.Asn739Ser)SNV Uncertain significance 323241 rs886052941 17:40468848-40468848 17:42316830-42316830
36 STAT3 NM_139276.2(STAT3):c.-55C>GSNV Uncertain significance 323249 rs886052944 17:40540328-40540328 17:42388310-42388310
37 STAT3 NM_139276.2(STAT3):c.-195G>CSNV Uncertain significance 323252 rs780393027 17:40540468-40540468 17:42388450-42388450
38 STAT3 NM_139276.2(STAT3):c.*2002G>ASNV Uncertain significance 323211 rs531760487 17:40465761-40465761 17:42313743-42313743
39 STAT3 NM_139276.2(STAT3):c.*2343deldeletion Uncertain significance 323206 rs886052929 17:40465420-40465420 17:42313402-42313402
40 STAT3 NM_139276.2(STAT3):c.*1673C>TSNV Uncertain significance 323217 rs886052935 17:40466090-40466090 17:42314072-42314072
41 STAT3 NM_139276.2(STAT3):c.*1415C>GSNV Uncertain significance 323221 rs886052936 17:40466348-40466348 17:42314330-42314330
42 STAT3 NM_139276.2(STAT3):c.*260G>ASNV Uncertain significance 323239 rs886052940 17:40467503-40467503 17:42315485-42315485
43 STAT3 NM_139276.2(STAT3):c.*1270C>TSNV Uncertain significance 323225 rs886052937 17:40466493-40466493 17:42314475-42314475
44 STAT3 NM_139276.2(STAT3):c.1101C>G (p.Cys367Trp)SNV Uncertain significance 323246 rs886052942 17:40483498-40483498 17:42331480-42331480
45 DOCK8 NM_203447.3(DOCK8):c.277G>T (p.Val93Leu)SNV Uncertain significance 366537 rs375686155 9:286581-286581 9:286581-286581
46 DOCK8 NM_203447.3(DOCK8):c.3195G>A (p.Arg1065=)SNV Uncertain significance 366968 rs781062154 9:399220-399220 9:399220-399220
47 DOCK8 NM_203447.3(DOCK8):c.*845T>CSNV Uncertain significance 367104 rs10157 9:465064-465064 9:465064-465064
48 DOCK8 NM_203447.3(DOCK8):c.1623C>G (p.His541Gln)SNV Uncertain significance 366676 rs200201944 9:340265-340265 9:340265-340265
49 DOCK8 NM_203447.3(DOCK8):c.2527G>A (p.Gly843Arg)SNV Uncertain significance 366881 rs886063934 9:379857-379857 9:379857-379857
50 DOCK8 NM_203447.3(DOCK8):c.2740G>A (p.Ala914Thr)SNV Uncertain significance 366928 rs375665207 9:382647-382647 9:382647-382647
Sources

Expression for Hyper Ige Syndrome

About this section
Search GEO for disease gene expression data for Hyper Ige Syndrome.
Sources

Pathways for Hyper Ige Syndrome

About this section

Pathways related to Hyper Ige Syndrome according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 65
Show member pathways
 13.08 STAT3 IL6ST IL4R IL4 IGHE IFNG
2
Pathways in cancer 36
12.53 STAT3 IL6ST IL4R IL4 IFNG
3
Immune response NFAT in immune response 22
Show member pathways
 12.39 IL4R IL4 IGHE IFNG
4
NF-kappaB Signaling 4
12.33 STAT3 IL6ST IL4 IFNG
5
Development IGF-1 receptor signaling 22
Show member pathways
 12.14 STAT3 IL4R IL4 IGHE
6
Th17 cell differentiation 36
Show member pathways
 12.09 STAT3 IL6ST IL4R IL4 IFNG
7
IL-17 Family Signaling Pathways 64
Show member pathways
 12.07 STAT3 IL6ST IL4 IFNG
8
Toxoplasmosis 36
Show member pathways
 12.04 STAT3 IL4 IFNG
9
Th1 Differentiation Pathway 64
Show member pathways
 11.84 STAT3 IL6ST IFNG
10
IL12-mediated signaling events 1
Show member pathways
 11.75 STAT3 IL4 IFNG
11
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.64 STAT3 IFNG
12
Jak-Stat Signaling Pathway (sino) 66
11.5 STAT3 IL6ST IL4R IFNG
13
IL4-mediated signaling events 1
11.45 IL4R IL4 IGHE
14
JAK-STAT signaling pathway (KEGG) 36
Show member pathways
 11.39 STAT3 IL6ST IL4R IL4 IFNG
15
Interleukin-4 and 13 signaling 65
11.31 STAT3 IL4R IL4 IGHE
16
Th2 Differentiation Pathway 64
11.21 IL4R IL4 IFNG
17
Immune response_IL-6 signaling pathway 22
11.14 STAT3 IL6ST
18
Development and heterogeneity of the ILC family 1
11.12 IL4 IFNG
19
Immune response_IL-12 signaling pathway 22
Show member pathways
 11.07 STAT3 IFNG
20
Cytokines and Inflammatory Response 1
11.06 IL4 IFNG
21
IL12 signaling mediated by STAT4 1
11.04 STAT3 IFNG
22
Inflammatory Response Pathway 1
11.02 IL4R IL4 IFNG
23
OX40 Pathway 63
10.99 IL4 IFNG
24
Physiological and Pathological Hypertrophy of the Heart 1
10.97 STAT3 IL6ST
25
Immune response_Oncostatin M signaling via JAK-Stat in human cells 22
10.84 STAT3 IL6ST
Sources

GO Terms for Hyper Ige Syndrome

About this section

Biological processes related to Hyper Ige Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.78 IL4R IL4 IGHE IFNG
2 JAK-STAT cascade GO:0007259 9.49 STAT3 IFNG
3 interleukin-6-mediated signaling pathway GO:0070102 9.46 STAT3 IL6ST
4 positive regulation of ATP biosynthetic process GO:2001171 9.43 STAT3 IL4
5 interleukin-35-mediated signaling pathway GO:0070757 9.4 STAT3 IL6ST
6 interleukin-27-mediated signaling pathway GO:0070106 9.37 STAT3 IL6ST
7 cytokine-mediated signaling pathway GO:0019221 9.35 STAT3 IL6ST IL4R IL4 IGHE
8 positive regulation of MHC class II biosynthetic process GO:0045348 9.32 IL4 IFNG
9 neuroinflammatory response GO:0150076 9.26 IL4 IFNG
10 positive regulation of cellular respiration GO:1901857 9.16 IL4 IFNG
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 8.92 STAT3 IL6ST IL4 IFNG
Sources

Sources for Hyper Ige Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....